Literature DB >> 19822038

How did ankylosing spondylitis become a separate disease?

T G Benedek1.   

Abstract

Individual patients whose disease in retrospect is compatible with a diagnosis of ankylosing spondylitis (AS) began to be described in the 19th century, at a time when "rheumatism" comprised an undefined conglomeration of ailments. In the 1890s, rheumatoid arthritis (RA) began to be extricated from rheumatic fever and gout. But what criteria should delimit the diagnosis of RA? The first assistance came with the introduction of radiology in the first decade of the new century. By the 1930s, objective radiologic distinctions between RA and A S were being made, beginning with the preferential involvement of the sacroiliac joints in AS. The first useful serologic test was developed in the 1950s: "rheumatoid factor" that eventually is present in about three-fourths of cases of RA, but is absent in AS. In the 1970s discovery of clinical associations with specific histocompatibility antigens finalized the distinction between RA and AS with the discovery that one antigen, B-27, is associated ten times as frequently with AS than with RA, while it occurs no more frequently with RA than in the general population. Associations between B-27 and certain radiologic appearances has further been mutually confirmatory of their diagnostic significance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19822038

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  3 in total

1.  Case report--progressive immobilising back and joint pain.

Authors:  Titus Divala; Jamie Rylance
Journal:  Malawi Med J       Date:  2011-06       Impact factor: 0.875

Review 2.  Nonradiographic axial spondyloarthritis: expanding the spectrum of an old disease: A narrative review.

Authors:  Marina Magrey; Sergio Schwartzman; Natasha de Peyrecave; Victor S Sloan; Jeffrey L Stark
Journal:  Medicine (Baltimore)       Date:  2022-04-15       Impact factor: 1.817

3.  S100A8/A9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis.

Authors:  Edwin J W Geven; Martijn H J van den Bosch; Irene Di Ceglie; Giuliana Ascone; Shahla Abdollahi-Roodsaz; Annet W Sloetjes; Sven Hermann; Michael Schäfers; Fons A J van de Loo; Peter M van der Kraan; Marije I Koenders; Dirk Foell; Johannes Roth; Thomas Vogl; Peter L E M van Lent
Journal:  Arthritis Res Ther       Date:  2016-10-24       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.